Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Eli Lilly and Company ... sales for Mounjaro and Zepbound fell well short of initial analyst predictions. Estimates for this earnings release were reset after the firm released a preliminary ...
After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...
For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...
After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE ... while revenue for Zepbound surged from $175.8 million to $1.9 billion.
After reducing its guidance last month, Eli ... Lilly's growth was led by its GLP-1 drugs. For the quarter, revenue for Mounjaro soared 60% year over year to $3.5 billion, while revenue for ...
A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...
The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...